Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
434
Recruiting, any sponsor type, condition "ovarian cancer"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting434
- Completed1,620
434 trials
Showing 1 to 25, recently updated first.
Haihua YuanAcademic, hospital or other
NCT07631871 · 10 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2029
Drug: Zanidatamab · For: Neoplasms; Solid Tumors; HER2 Positive Solid Tumor and 7 more
Sites: Shanghai, China
PhotonPharma, Inc.Industry
NCT06366490 · 12 participants (planned) · Start Feb 12, 2026 · Primary completion Nov 2028
Drug: Innocell · For: Ovarian Cancer (OvCa)
Sites: Duarte, California
Whitehawk Therapeutics, Inc.Industry
NCT07444814 · 226 participants (planned) · Start Dec 19, 2025 · Primary completion Sep 2028
Drug: HWK-007 · For: Endometrial Cancer; Ovarian Cancer; Ovarian Cancer Metastatic and 4 more
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 17 sites in all
- DESTINY-PANTUMOUR04Recruiting
AstraZenecaAstraZeneca (AZN)
NCT07124000 · 100 participants (planned) · Start Sep 18, 2025 · Primary completion Mar 30, 2028
Drug: Trastuzumab deruxtecan · For: Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer and 24 more
Sites: Birmingham, Alabama; Bullhead City, Arizona; Casa Grande, Arizona · 18 sites in all
National Cancer Institute (NCI)NIH
NCT04847063 · 60 participants (planned) · Start Oct 19, 2021 · Primary completion Dec 30, 2033
Drug: Sodium Thiosulfate; 5-Fluorouracil and 4 more · For: Peritoneal Mesothelioma; Peritoneal Carcinomatosis; Ovarian Cancer and 4 more
Sites: Bethesda, Maryland
Regor Pharmaceuticals Inc.Industry
NCT07524322 · 63 participants (planned) · Start Jul 21, 2026 · Primary completion Apr 2028
Drug: RGT-490 · For: Breast Cancer; Ovarian Cancer; Endometrial Cancer and 6 more
Sites: Los Angeles, California; Boston, Massachusetts; Pittsburgh, Pennsylvania · 7 sites in all
National Cancer Institute (NCI)NIH
NCT07504588 · 87 participants (planned) · Start Sep 24, 2026 · Primary completion Apr 12, 2029
Drug: Anti-VEGF Monoclonal Antibody; Bevacizumab and 4 more · For: Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma and 3 more
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 29 sites in all
- A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.Recruiting
Outpace Bio, Inc.Industry
NCT07664735 · 30 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2030
Drug: OPB-201 · For: Endometrial Cancer Recurrent; Endometrial Cancer; Advanced Endometrial Cancer and 4 more
Sites: San Francisco, California; Atlanta, Georgia; Detroit, Michigan · 5 sites in all
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruiting
National Cancer Institute (NCI)NIH
NCT06503146 · 320 participants (planned) · Start Sep 9, 2025 · Primary completion Jun 1, 2028
Drug: [18F]FAPI-74; [18F]FDG · For: Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma and 7 more
Sites: Bethesda, Maryland
University of Alabama at BirminghamAcademic, hospital or other
NCT05952453 · 20 participants (planned) · Start Feb 17, 2025 · Primary completion Oct 30, 2028
Drug: Carboplatin; olaparibp, embro · For: Ovarian Cancer
Sites: Birmingham, Alabama
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
Second Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT06660511 · 5 participants (planned) · Start Oct 15, 2024 · Primary completion Dec 1, 2026
Drug: Disitamab Vedotin in Combination With Anlotinib Hydrochloride · For: Ovarian Cancer Recurrent
Sites: Changsha, China
Shanghai Gynecologic Oncology GroupGovernment (non-federal)
NCT07674615 · 19 participants (planned) · Start Sep 2, 2026 · Primary completion Jun 30, 2027
Drug: Sacituzumab govitecan monotherapy · For: Epithelial Ovarian Cancer; Fallopian Tube Cancers; Primary and 1 more
Sites: Shanghai, China
- A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07488676 · 150 participants (planned) · Start May 4, 2026 · Primary completion Jul 31, 2029
Drug: ASP546C · For: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma; Pancreatic Adenocarcinoma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 35 sites in all
National Cancer Institute (NCI)NIH
NCT04585958 · 55 participants (planned) · Start May 21, 2021 · Primary completion Dec 31, 2026
Drug: Olaparib; Trastuzumab Deruxtecan · For: Metastatic Malignant Solid Neoplasm; Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma; Unresectable Malignant Solid Neoplasm
Sites: Phoenix, Arizona; Coral Gables, Florida; Deerfield Beach, Florida · 13 sites in all
National Cancer Institute (NCI)NIH
NCT05950464 · 65 participants (planned) · Start Dec 18, 2023 · Primary completion Jun 30, 2027
Drug: BET Bromodomain Inhibitor ZEN-3694; Tuvusertib · For: Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma and 6 more
Sites: Augusta, Georgia; Chicago, Illinois; Iowa City, Iowa · 14 sites in all
National Cancer Institute (NCI)NIH
NCT05112601 · 81 participants (planned) · Start Jun 2, 2022 · Primary completion Jul 30, 2032
Drug: Ipilimumab; Nivolumab · For: Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma and 6 more
Sites: Birmingham, Alabama; Athens, Georgia; Augusta, Georgia · 138 sites in all
- Study of NTB-928 in R/R OCRecruiting
TeneoSeven, Inc.Industry
NCT07690189 · 90 participants (planned) · Start Jun 29, 2026 · Primary completion Jun 2028
Drug: NTB-928 · For: Relapsed/Refractory Ovarian Carcinoma
Sites: Birmingham, Alabama; San Francisco, California; Aurora, Colorado · 5 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT05321316 · 40 participants (planned) · Start May 31, 2025 · Primary completion Dec 2026
Drug: 18F-FDG · For: Urothelial Carcinoma; Breast Cancer; Lung Cancer and 3 more
Sites: Beijing, China
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07318558 · 900 participants (planned) · Start Feb 16, 2026 · Primary completion Feb 25, 2033
Drug: Sacituzumab tirumotecan; Bevacizumab and 1 more · For: Ovarian Neoplasms; Ovarian Cancer
Sites: Birmingham, Alabama; La Jolla, California; Newport Beach, California · 178 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06824467 · 770 participants (planned) · Start Apr 9, 2025 · Primary completion Apr 27, 2029
Drug: Sacituzumab tirumotecan; Bevacizumab and 5 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Duarte, California · 203 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06172478 · 890 participants (planned) · Start Feb 26, 2024 · Primary completion Nov 19, 2030
Drug: HER3-DXd · For: Advanced Solid Tumor; Melanoma; Head and Neck Cancer and 11 more
Sites: Duarte, California; New Haven, Connecticut; Kissimmee, Florida · 97 sites in all
- A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07776691 · 802 participants (planned) · Start Sep 18, 2026 · Primary completion Mar 19, 2032
Drug: R-DXd; Bevacizumab · For: Ovarian Cancer; Ovarian Neoplasms; Peritoneal Cancer and 1 more
Sites: Washington D.C., District of Columbia; Burlington, Massachusetts; Columbus, Ohio · 18 sites in all
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT05990192 · 42 participants (planned) · Start Jun 20, 2024 · Primary completion Dec 31, 2027
Drug: Niraparib oral capsule · For: Ovarian Cancer Recurrent
Sites: Leeds, United Kingdom; Leicester, United Kingdom; Manchester, United Kingdom · 8 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.